Tonix Pharmaceuticals Holding Forum: Community User: StefanN19

Net schlecht und das zur mittags zeit

Von - 1,3 % auf + ca. 8 % vorbörslich gespurungen

8,1 mio ist okay für den Anfang

Immerhin stark

6,7 mio

5,1 mio Handel, die wollen wohl noch nicht so richtig 🤔

Zieht

Drüben über 2 mio Handel bis jetzt

👍

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001), a study of humoral (antibody) and cellular (T cell) immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s TNX-1800, which is a live replicating, attenuated virus vaccine designed to protect against COVID-19. “This represents a significant milestone for the Company as the data we plan to collect from recovered and asymptomatic COVID-19 volunteers in this study will help inform vaccine development on how to safely provide the same immune responses that others got from recovering from actual SARS-CoV-2 infection,” said Seth Lederman, M.D., President and CEO of Tonix. “Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed. The features of a protective immune response to SARS-CoV-2 remain unknown. But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or TH1 responses, will play an important, if not dominant, role in protecting against serious illness from COVID-19.”

Wann wäre die nächste frist

Warum sollte ein RS so schnell drohen? Haben doch erst vor 1 Monat die Auflage erfüllt: EW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. The Company received a letter from The NASDAQ Stock Market LLC on August 3, 2020 stating that because its shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(a)(1), and the matter is now closed

Beobachte lieber anstelle einzusteigen

🤦‍♂️

wenn dann geh ich mit spielgeld rein und nicht wie zuletzt als ich wochenlang echte Magenschmerzen hatte

ich schaue bis ende September, vielleicht habt ihr mich dann wieder am Bein. Droht aktuell ein nächster Reverse Split?